Does Rallies show Form 4 insider transactions for CRBP?

Yes. Rallies tracks CRBP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CRBP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CRBP. It does not provide personalized investment advice.

CRBP (Corbus Pharmaceuticals Holdings, Inc.) Stock Analysis - Insider Trades

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a publicly traded Healthcare sector company. As of May 21, 2026, CRBP trades at $9.93 with a market cap of $184.35M and a P/E ratio of -1.68. CRBP moved +6.56% today. Year to date, CRBP is +24.27%; over the trailing twelve months it is +28.53%. Its 52-week range spans $4.64 to $22.20. Analyst consensus is strong buy with an average price target of $40.78. Rallies surfaces CRBP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CRBP stock inside the company?

Recent CRBP insider activity includes Smethurst Dominic sold 6.10K, Hodgson Ian sold 847, Moran Sean F. sold 4.70K, Cohen Yuval sold 13.87K, and Smethurst Dominic sold 3.29K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CRBP Key Metrics

Key financial metrics for CRBP
Metric	Value
Price	$9.93
Market Cap	$184.35M
P/E Ratio	-1.68
EPS	$-5.74
Dividend Yield	0.00%
52-Week High	$22.20
52-Week Low	$4.64
Volume	1.29K
Avg Volume	0
Revenue (TTM)	$5.25M
Net Income	$-84.53M
Gross Margin	0.00%

Recent CRBP Insider Trades

Smethurst Dominic sold 6.10K (~$50.60K) on Mar 2, 2026.
Hodgson Ian sold 847 (~$6.25K) on Feb 17, 2026.
Moran Sean F. sold 4.70K (~$36.59K) on Feb 13, 2026.
Cohen Yuval sold 13.87K (~$107.95K) on Feb 13, 2026.
Smethurst Dominic sold 3.29K (~$26.57K) on Feb 3, 2026.

Latest CRBP News

Corbus Appoints Ex-BMS Oncology Head Pfeiffenberger to Drive CRB-701 Registration Study — May 14, 2026
Corbus Gains FDA Alignment for CRB-701, Completes 240-Patient Obesity Trial — May 12, 2026
Corbus to Present Phase 1/2 CRB-701 Durability Data at ASCO, Plans HNSCC Trial — Apr 22, 2026
Corbus Pharmaceuticals Completes Enrollment in 240-Patient 20/40/60mg Phase 1b Obesity Trial — Apr 14, 2026
Corbus Secures FDA Nod for CRB-701 Trials in Second-Line HNSCC and Cervical Cancer — Apr 7, 2026

CRBP Analyst Consensus

10 analysts cover CRBP: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $40.78.

Common questions about CRBP

Who is trading CRBP stock inside the company?: Recent CRBP insider activity includes Smethurst Dominic sold 6.10K, Hodgson Ian sold 847, Moran Sean F. sold 4.70K, Cohen Yuval sold 13.87K, and Smethurst Dominic sold 3.29K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CRBP?: Yes. Rallies tracks CRBP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CRBP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CRBP. It does not provide personalized investment advice.